Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences to Report Third Quarter Results on November 7, 2023

Wednesday, November 1, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences, Inc. is scheduled to report its third quarter results on November 7, 2023. The company focuses on advanced gene editing using its proprietary ARCUS platform, which allows for sophisticated gene edits such as insertion, excision, and elimination. This announcement highlights the company's ongoing development in the field of gene therapies.
Price reaction · baseline $9.234 (2023-10-31 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close
+29.6%
day 1 · peak
+30%
day 3
+29.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Precision BioSciences is advancing gene editing technology.
  • The company is set to report third quarter results, indicating progress.
  • Utilization of the proprietary ARCUS platform shows innovation.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–Nov. 1, 2023– Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination,

Frequently Asked Questions

When will Precision BioSciences report its Q3 results?

Precision BioSciences will report its third quarter results on November 7, 2023.

What platform does Precision BioSciences use?

The company utilizes its proprietary ARCUS platform for gene editing therapies.

What types of gene edits can ARCUS perform?

ARCUS can perform gene insertion, excision, and elimination.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences gene editing ARCUS platform third quarter results
Last updated: Nov 1, 2023

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →